7 min. Read

Genentech-Roche VR for autism. FDA’s new remote monitoring waiver.

Issue 044.

Get E&O weekly. | Subscribe

Digital health research from Brian Dolan.

Welcome to E&O.

Last week's newsletter had a 59 percent open rate. Here's what's happening this week:

  • A pandemic. My plan is to cover coronavirus-related developments only if they impact the future of digital health interventions in some meaningful way. So, this week's edition of E&O will include a few. For example, the crisis has triggered some important regulatory rollbacks that will likely lead to long-term changes -- much more on that after the jump.
  • One quick follow-up to my Sanofi-Verily-Onduo-Dexcom writeup from last week. Verily paid Sanofi $122 million worth of Dexcom stock as a dividend following the restructuring of Onduo, which saw Sanofi's share reduced from 50 percent to 19.9 percent. This is oversimplifying it, but, in effect, Verily paid Sanofi $122 million for 30.1 percent of Onduo.

Paying Subscribers Only

It's a good one, too.
This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!

Full access to E&O's research and newsletters.

Get the subscribers-only newsletters + research reports + databases
Facebook’s RCT for AI bot Zenny. More trials
7 min. Read
FDA de novo for Google smartphone thermometer.
6 min. Read
PDT-to-virtual-clinic trend continues. HCPCS tweaks.
8 min. Read
Mahana Tinnitus. New CPT hopefuls. Better cuts salaries
6 min. Read
CMS weighs HCPCS for Natural Cycles, Leva, and Tyto. Plus: Akili Q3 results.
8 min. Read
metaMe Health seeks buyer by year-end. CMS offers up digital therapeutics nothingburger
6 min. Read
PDT Pipeline changes. Kinsa shuts down. Trials
5 min. Read
CPT decisions. Trials: Big Health, Mahana and more
6 min. Read
Akili CEO steps down. Aetna rolls back some virtual care coverage
5 min. Read
Biogen cuts digital, MedRhythms, Apple. Pfizer on PDTs.
6 min. Read
  • First
  • Previous
  • 1 of 20
  • Next
  • Last